ImmunoCellular Therapeutics Enters into an Agreement with UMB to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms
Wednesday, January 27, 2016
ImmunoCellular Therapeutics, Ltd. today announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and the University of Maryland, Baltimore. The agreement includes three projects, which together have the potential to improve the efficacy of dendritic cell, T-cell, and combination immunotherapies for cancer and lead to enhancements to both of ImmunoCellular's dendritic cell and Stem-to-T-cell platforms.